• Username (E-mail)
  • Password
Dow 20,822 0.1%  EStoxx50 3,304 -0.9%  Nikkei 19,284 -0.5%  EUR 1.0566 0.0% 
Nasdaq 5,845 0.2%  FTSE100 7,244 -0.4%  Yen 112.1450 0.0%  Oil 56.0 -0.8% 
S&P500 2,367 0.2%  DAX 11,804 -1.2%  GBP 1.2480 0.2%  Gold 1,257 0.0% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

12/05/2012 07:59:30 AM
12/05/2012 07:59:30 AM UTC-0500

Vertex Pharmaceuticals Inc. Outperform

The analysts of RBC Capital Markets have rated Vertex Pharmaceuticals with a Outperform rating. The price target was set to 70.00 $. At a current price of the Vertex Pharmaceuticals stock of 86.02 $ this means a downside potential of -18.62%.
Summary: Vertex Pharmaceuticals Inc. Outperform
Company:
Vertex Pharmaceuticals Inc.
Analyst:
RBC Capital Markets
Price Target:
70.00 $
Current Rating:
Outperform
Price*:
39.21 $
Distance to Target Price*:
78.53%
Previous Rating:
n/A
Latest Price:
86.02 $
Distance Price Target:
-18.62%
Analyst Name::
Charmaine Chan
P/E Ratio*:
-

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/14/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
12/05/12
Vertex Pharmaceuticals RBC Capital Markets
11/13/12
Vertex Pharmaceuticals Credit Suisse Group
11/05/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
11/02/12
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Latest Analyst Opinions
02/24/17 Salzgitter Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02/24/17 RHÖN-KLINIKUM DZ BANK
02/24/17 General Electric (GE) Bernstein Research
02/24/17 freenet equinet AG
02/24/17 GFT Technologies equinet AG
02/24/17 Deutsche Telekom equinet AG
02/24/17 ElringKlinger equinet AG
02/24/17 Banco Bilbao Vizcaya Argentaria Société Générale Group S.A. (SG)
02/24/17 Banco Santander Central Hispano Société Générale Group S.A. (SG)
02/24/17 Airbus Norddeutsche Landesbank (Nord/LB)
02/24/17 Wirecard DZ BANK
02/24/17 International Consolidated Airlines Group S&P Capital IQ
02/24/17 Vivendi Barclays Capital
02/24/17 Nordex Norddeutsche Landesbank (Nord/LB)
02/24/17 TAG Immobilien Oddo Seydler Bank AG
02/24/17 STADA Arzneimittel Independent Research GmbH
02/24/17 ADVA Optical Networking Oddo Seydler Bank AG
02/24/17 DIC Asset Oddo Seydler Bank AG
02/24/17 XING Oddo Seydler Bank AG
02/24/17 thyssenkrupp DZ BANK
02/24/17 Dürr Baader Bank
02/24/17 RHÖN-KLINIKUM Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02/24/17 BASF Kepler Cheuvreux
02/24/17 Compagnie de Saint-Gobain Morgan Stanley
02/24/17 BASF S&P Capital IQ
02/24/17 Peugeot Kepler Cheuvreux
02/24/17 Dürr Goldman Sachs Group Inc.
02/24/17 Continental Jefferies & Company Inc.
02/24/17 TAG Immobilien Kepler Cheuvreux
02/24/17 GERRY WEBER International Independent Research GmbH
02/24/17 STADA Arzneimittel DZ BANK
02/24/17 WCM Beteiligungs- und Grundbesitz-AG Warburg Research
02/24/17 DIC Asset DZ BANK
02/24/17 British American Tobacco Barclays Capital
02/24/17 Vivendi S&P Capital IQ
02/24/17 Zurich Insurance Group Jefferies & Company Inc.
02/24/17 OSRAM Licht Kepler Cheuvreux
02/24/17 MTU Aero Engines Independent Research GmbH
02/24/17 AIXTRON Warburg Research
02/24/17 Nordex Independent Research GmbH
02/24/17 Nordex Warburg Research
02/24/17 RHÖN-KLINIKUM S&P Capital IQ
02/24/17 Michelin (Compagnie Générale d Etablissements Michelin SCPA) Jefferies & Company Inc.
02/24/17 BNP Paribas Jefferies & Company Inc.
02/24/17 BASF Independent Research GmbH
02/24/17 Dürr Kepler Cheuvreux
02/24/17 Unilever Credit Suisse Group
02/24/17 Société Générale SA Jefferies & Company Inc.
02/24/17 Fielmann Independent Research GmbH
02/24/17 Deutsche Telekom Deutsche Bank AG